TW201625620A - 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法 - Google Patents
作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法 Download PDFInfo
- Publication number
- TW201625620A TW201625620A TW104115502A TW104115502A TW201625620A TW 201625620 A TW201625620 A TW 201625620A TW 104115502 A TW104115502 A TW 104115502A TW 104115502 A TW104115502 A TW 104115502A TW 201625620 A TW201625620 A TW 201625620A
- Authority
- TW
- Taiwan
- Prior art keywords
- aryl
- heteroaryl
- alkyl
- substituted
- cycloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461996691P | 2014-05-14 | 2014-05-14 | |
| US201461996702P | 2014-05-14 | 2014-05-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW201625620A true TW201625620A (zh) | 2016-07-16 |
Family
ID=54480695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104115502A TW201625620A (zh) | 2014-05-14 | 2015-05-14 | 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US9840520B2 (https=) |
| EP (1) | EP3142652B1 (https=) |
| JP (1) | JP6803235B2 (https=) |
| KR (1) | KR20170003688A (https=) |
| CN (1) | CN106456580B (https=) |
| BR (1) | BR112016026518A2 (https=) |
| CA (1) | CA2949163A1 (https=) |
| MX (1) | MX2016014911A (https=) |
| RU (1) | RU2016148863A (https=) |
| TW (1) | TW201625620A (https=) |
| WO (1) | WO2015175813A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016005199B1 (pt) | 2013-08-23 | 2022-02-22 | Neupharma, Inc | Certos compostos químicos, composições, e métodos |
| US9840520B2 (en) | 2014-05-14 | 2017-12-12 | The Regents Of The University Of Colorado, A Body Corporate | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
| WO2016095881A1 (en) * | 2014-12-15 | 2016-06-23 | Univerzita Palackeho V Olomouci | Substituted 6-anilino-9-heterocyclylpurine derivatives for inhibition of plant stress |
| EP3270694A4 (en) * | 2015-02-17 | 2018-09-05 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| CN106831780A (zh) * | 2015-12-03 | 2017-06-13 | 南开大学 | 具有cdk4/6和hdac抑制活性的新型杂环衍生物 |
| WO2018035061A1 (en) | 2016-08-15 | 2018-02-22 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
| KR102477063B1 (ko) * | 2016-10-28 | 2022-12-12 | 브리스톨-마이어스 스큅 컴퍼니 | Il-12, il-23 및/또는 ifn 알파 반응의 조정제로서 유용한 헤테로비시클릭 화합물 |
| IT201700041723A1 (it) * | 2017-04-14 | 2018-10-14 | Italfarmaco Spa | Nuovi inibitori selettivi di HDAC6 |
| CN107513064B (zh) * | 2017-09-27 | 2019-07-09 | 南昌大学 | 一种嘌呤异羟肟酸衍生物及其制备方法和应用 |
| KR20190043437A (ko) | 2017-10-18 | 2019-04-26 | 씨제이헬스케어 주식회사 | 단백질 키나제 억제제로서의 헤테로고리 화합물 |
| KR102195348B1 (ko) | 2018-11-15 | 2020-12-24 | 에이치케이이노엔 주식회사 | 단백질 키나제 억제제로서의 신규 화합물 및 이를 포함하는 약제학적 조성물 |
| KR102847312B1 (ko) * | 2021-12-30 | 2025-08-19 | 한국화학연구원 | 피라졸로피리미딘 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| EP4458827A4 (en) * | 2021-12-30 | 2025-10-29 | Korea Res Inst Chemical Tech | PYRAZOLOPYRIMIDINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION CONTAINING IT AS THE ACTIVE INGREDIENT |
| CN114685507B (zh) * | 2022-04-06 | 2024-01-12 | 山东大学 | 嘌呤胺衍生物类cdk2抑制剂及其制备方法和应用 |
| KR102792443B1 (ko) * | 2022-05-13 | 2025-04-08 | 서울대학교산학협력단 | Cdk를 저해하는 신규 피롤로피리미디논 카복사미드 화합물, 이의 입체이성질체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암 치료용 약학적 조성물 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998039326A1 (en) | 1997-03-04 | 1998-09-11 | Monsanto Company | Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds |
| US6638952B1 (en) * | 1997-03-04 | 2003-10-28 | Pharmacia Corporation | Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds |
| NZ337326A (en) | 1997-03-04 | 2001-05-25 | Monsanto Co | Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds to inhibit the activity of matrix metalloproteinases |
| WO1999025687A1 (en) * | 1997-11-14 | 1999-05-27 | G.D. Searle & Co. | Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| US20020049237A1 (en) | 1998-03-17 | 2002-04-25 | Newton Roger Schofield | Statin-MMP inhibitor combinations |
| AU2002246983A1 (en) * | 2001-01-11 | 2002-07-24 | Bristol-Myers Squibb Pharma Company | 1,2-disubstituted cyclic inhibitors of matrix metallorproteases and tnf-alpha |
| JPWO2002074298A1 (ja) * | 2001-03-21 | 2004-07-08 | 小野薬品工業株式会社 | Ｉｌ−６産生阻害剤 |
| PE20030701A1 (es) * | 2001-12-20 | 2003-08-21 | Schering Corp | Compuestos para el tratamiento de trastornos inflamatorios |
| AU2003900608A0 (en) * | 2003-02-11 | 2003-02-27 | Fujisawa Pharmaceutical Co., Ltd. | Hdac inhibitor |
| BRPI0409227C1 (pt) * | 2003-04-07 | 2021-05-25 | Axys Pharm Inc | composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i) |
| CA2532403A1 (en) * | 2003-07-17 | 2005-02-03 | James Arnold | Ppar active compounds |
| DK1981871T3 (da) * | 2006-01-19 | 2012-02-13 | Janssen Pharmaceutica Nv | Heterocyclylalkylderivater som hidtil ukendte inhibitorer af histondeacetylase |
| WO2008053131A1 (en) | 2006-10-30 | 2008-05-08 | Chroma Therapeutics Ltd. | Hydroxamates as inhibitors of histone deacetylase |
| CA2673965A1 (en) | 2006-12-28 | 2008-07-10 | Taisho Pharmaceutical Co., Ltd. | Pyrazolopyrimidine compound |
| WO2009036066A1 (en) * | 2007-09-10 | 2009-03-19 | Curis, Inc. | Vegfr inhibitors containing a zinc binding moiety |
| WO2009036020A1 (en) | 2007-09-10 | 2009-03-19 | Curis, Inc. | Mek inhibitors containing a zinc binding moiety |
| KR101168801B1 (ko) * | 2009-03-27 | 2012-07-25 | 주식회사종근당 | 신규한 하이드록사메이트 유도체, 이의 제조방법, 및 이를 함유하는 약제학적 조성물 |
| PH12012501492B1 (en) * | 2010-01-22 | 2020-01-24 | Acetylon Pharmaceuticals Inc | Reverse amide compounds as protein deacetylase inhibitors and methods of use thereof |
| US8513421B2 (en) * | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| WO2012170827A2 (en) | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines and related heterocycles as ck2 inhibitors |
| WO2013041407A1 (en) | 2011-09-19 | 2013-03-28 | Cellzome Ag | Hydroxamic acids as hdac6 inhibitors |
| KR20140118575A (ko) * | 2013-03-29 | 2014-10-08 | 한미약품 주식회사 | 신규한 하이드록사메이트 유도체 |
| US9840520B2 (en) | 2014-05-14 | 2017-12-12 | The Regents Of The University Of Colorado, A Body Corporate | Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof |
-
2015
- 2015-05-14 US US15/310,743 patent/US9840520B2/en not_active Ceased
- 2015-05-14 CN CN201580024748.8A patent/CN106456580B/zh active Active
- 2015-05-14 EP EP15792349.1A patent/EP3142652B1/en active Active
- 2015-05-14 US US15/968,188 patent/USRE47690E1/en active Active
- 2015-05-14 WO PCT/US2015/030842 patent/WO2015175813A1/en not_active Ceased
- 2015-05-14 KR KR1020167035003A patent/KR20170003688A/ko not_active Withdrawn
- 2015-05-14 TW TW104115502A patent/TW201625620A/zh unknown
- 2015-05-14 MX MX2016014911A patent/MX2016014911A/es unknown
- 2015-05-14 BR BR112016026518A patent/BR112016026518A2/pt not_active IP Right Cessation
- 2015-05-14 CA CA2949163A patent/CA2949163A1/en not_active Abandoned
- 2015-05-14 RU RU2016148863A patent/RU2016148863A/ru unknown
- 2015-05-14 JP JP2016567524A patent/JP6803235B2/ja not_active Expired - Fee Related
-
2017
- 2017-07-19 US US15/654,662 patent/US10508122B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20170081343A1 (en) | 2017-03-23 |
| CN106456580B (zh) | 2020-09-04 |
| EP3142652A1 (en) | 2017-03-22 |
| BR112016026518A2 (pt) | 2017-08-15 |
| CN106456580A (zh) | 2017-02-22 |
| WO2015175813A1 (en) | 2015-11-19 |
| RU2016148863A3 (https=) | 2018-12-17 |
| CA2949163A1 (en) | 2015-11-19 |
| EP3142652B1 (en) | 2021-08-25 |
| MX2016014911A (es) | 2017-04-06 |
| US20180044352A1 (en) | 2018-02-15 |
| USRE47690E1 (en) | 2019-11-05 |
| RU2016148863A (ru) | 2018-06-18 |
| US10508122B2 (en) | 2019-12-17 |
| JP2017515848A (ja) | 2017-06-15 |
| KR20170003688A (ko) | 2017-01-09 |
| EP3142652A4 (en) | 2017-11-29 |
| JP6803235B2 (ja) | 2020-12-23 |
| US9840520B2 (en) | 2017-12-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW201625620A (zh) | 作為蛋白去乙醯酶抑制劑及雙蛋白去乙醯酶蛋白激酶抑制劑之雜環氧肟酸及其使用方法 | |
| CN108314677B (zh) | 一种ezh2抑制剂及其用途 | |
| JP4405602B2 (ja) | ヒストン脱アセチル化酵素阻害剤 | |
| JP5840763B2 (ja) | ブロモドメイン阻害剤として有用なテトラヒドロキノリン誘導体 | |
| JP6059723B2 (ja) | ４−（８−メトキシ−１−（（１−メトキシプロパン−２−イル）−２−（テトラヒドロ−２Ｈ−ピラン−４−イル）−１Ｈ−イミダゾ［４，５−ｃ］キノリン−７−イル）−３，５−ジメチルイソオキサゾールおよびブロモドメイン阻害剤としてのその使用 | |
| JP5524343B2 (ja) | ベンゾジアゼピンブロモドメイン阻害剤 | |
| ES2911040T3 (es) | Nuevos derivados de heteroaril amida como inhibidores selectivos de histona deacetilasa 1 y 2 (HDAC1/2) | |
| CN105246887B (zh) | 香豆素衍生物以及用于治疗过度增生性疾病的方法 | |
| ES2871673T3 (es) | Activador de los canales KCNQ2-5 | |
| WO2018153293A1 (zh) | 二噁烷并喹唑啉与二噁烷并喹啉类化合物及其制备方法与应用 | |
| WO2013013614A1 (zh) | 4-(3-杂芳基芳基氨基)喹唑啉和1-(3-杂芳基芳基氨基)异喹啉作为Hedgehog通路抑制剂及其应用 | |
| CN112105602A (zh) | 基于喹啉和异喹啉的hdac抑制剂及其使用方法 | |
| TW201605805A (zh) | 喹唑啉酮及異喹啉酮衍生物 | |
| JP2024528251A (ja) | Ｈｄａｃとｎａｄ合成を標的とする多標的阻害剤及びその用途 | |
| AU2019218187A1 (en) | Dioxinoquinoline compounds, preparation method and uses thereof | |
| CN103648500A (zh) | 双功能酶制钳型分子的方法和用途 | |
| WO2018068357A1 (zh) | 一类新型sirt2蛋白抑制剂及其在制药中的用途 | |
| US11407760B2 (en) | Dioxinoquinoline compounds, preparation method and uses thereof | |
| WO2020114519A1 (zh) | 作为cdk-hdac双通路抑制剂的杂环化合物 | |
| CN111108083A (zh) | 氨基亚甲基环己烷1,3-二酮化合物的用途 | |
| JP7110335B2 (ja) | プロテインキナーゼ阻害剤として有用なピリドキナゾリン誘導体 | |
| TW202241517A (zh) | Usp5結合存活靶向嵌合(surtac)分子及其用途 | |
| CN109134433B (zh) | 一种抑制rock的化合物及其应用 | |
| HK1229722B (zh) | 作为蛋白质脱乙酰酶抑制剂和蛋白质脱乙酰酶-蛋白质激酶双重抑制剂的杂环异羟肟酸及其使用方法 | |
| CN117229229A (zh) | 一种抑制hdac6的苯并噻二嗪类化合物及其制备方法及应用 |